Advocacy intelligence hub — real-time data for patient organizations
Poitiers University Hospital
Damascus University
Kerckhoff Klinik
Rutgers, The State University of New Jersey
Beijing Chao Yang Hospital — NA
Irina E. Chazova
Suqiao Yang — PHASE3
Dr Sudarshan Rajagopal — PHASE3
Ester Ashraf Faried Beshay
Chinese University of Hong Kong — PHASE4
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Adempas
(riociguat)Orphan drugBayer
Soluble Guanylate Cyclase Stimulator [EPC]
12.1 Mechanism of Action Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system and the receptor for ni...
XARELTO
(RIVAROXABAN)standardJanssen Pharmaceuticals, Inc.
Factor Xa Inhibitor [EPC]
12.1 Mechanism of Action XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban...
Browse all Chronic thromboembolic pulmonary hypertension news →
Silvia Ulrich, MD
Respiratory Clinic, Departement Heart, Vessel, Thorax, University Hospital Zurich
Irene Lang, MD, RN, MS, CS
Medical University Vienna
📍 FALL RIVER, MA
Kim M Kerr, MD
UCSD Medical Center
Raffaele Pesavento, MD
University of Padova
Sudarshan Rajagopal, MD, PhD, M.D
Duke Health System
📍 DURHAM, NC
Joseph Mammarappallil, MD, PhD, MD
Duke University
📍 DURHAM, NC
View all Chronic thromboembolic pulmonary hypertension specialists →